Co-founder/President
Synakis
Synakis develops biomaterial-based therapies targeting ocular diseases, utilizing advanced polymer formulations to enhance drug delivery and tissue regeneration. The company addresses the need for effective treatments in a field with limited options for patients suffering from vision impairments.
- Biotechnology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Ocular diseases often lack effective treatments, leaving patients with limited options for vision impairments. Traditional drug delivery methods may not adequately target affected tissues, and regenerative therapies face challenges in promoting effective tissue repair in the eye.
Solution
Synakis develops biomaterial-based therapies designed to address ocular diseases through enhanced drug delivery and tissue regeneration. The company utilizes advanced polymer formulations to create targeted treatments. These therapies aim to improve the efficacy of drug delivery to specific areas of the eye, maximizing therapeutic impact while minimizing off-target effects. Synakis' approach also focuses on stimulating and supporting the natural regenerative processes within ocular tissues, potentially leading to improved outcomes for patients with various vision impairments.
Target Audience
Synakis' primary target audience includes patients suffering from ocular diseases and the ophthalmologists and medical professionals who treat them.
Features
- Advanced polymer formulations for targeted drug delivery to ocular tissues
- Biomaterial-based therapies designed to promote tissue regeneration in the eye